Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes

Applied and Environmental Microbiology

Volumn 78, Issue 3, 2012, Pages 744-751

  Edgar, Rotem ^a   Friedman, Nir ^a   Shahar, Molshanski Mor ^a   Qimron, Udi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-MICROBIAL AGENT; BACTERIAL RESISTANCE; HOMOLOGOUS RECOMBINATION; NALIDIXIC ACID; NOSOCOMIAL INFECTION; PATHOGEN RESISTANCE; PHAGE THERAPY; PROOF OF PRINCIPLES; RECOMBINATION EVENTS; SELECTION PRESSURES; SELECTIVE PRESSURE; SYSTEM USE; TOXIC COMPOUNDS;

BACTERIA; BACTERIOPHAGES; GENES; PATHOGENS; TELLURIUM COMPOUNDS;

ANTIBIOTICS;

ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); NALIDIXIC ACID; RECOMBINANT PROTEIN; RIBOSOME PROTEIN; STREPTOMYCIN; TELLURIUM; TELLUROUS ACID;

ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; BACTERIUM; GENE; PATHOGEN; TELLURITE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIOPHAGE; BACTERIUM; DOMINANT GENE; DRUG EFFECT; GENETIC SELECTION; GENETICS; LYSOGENIZATION; METABOLISM; VIROLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIOPHAGES; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; GENES, DOMINANT; LYSOGENY; NALIDIXIC ACID; RECOMBINANT PROTEINS; RIBOSOMAL PROTEINS; SELECTION, GENETIC; STREPTOMYCIN; TELLURIUM;

BACTERIA (MICROORGANISMS);

EID: 84855894994     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.05741-11     Document Type: Article

References (22)

1. Brussow H. 2005. Phage therapy: the Escherichia coli experience. Microbiology 151:2133-2140.
2. Drecktrah D, Douglas JM, Samuels DS. 2010. Use of rpsL as a counterselectable marker in Borrelia burgdorferi. Appl. Environ. Microbiol. 76:985-987.
3. Kimchi-Sarfaty C, et al. 2007. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528.
4. Komp Lindgren P, Karlsson A, Hughes D. 2003. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 47:3222-3232.
5. Lang LH. 2006. FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 131:1370.
6. Lederberg J. 1951. Streptomycin resistance; a genetically recessive mutation. J. Bacteriol. 61:549-550.
7. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10:S122-S129.
8. Lieb M. 1964. Ultraviolet sensitivity of Escherichia coli containing heatinducible lambda prophages. Science 145:175-176.
9. Liu M, Taylor DE. 1999. Characterization of gram-positive tellurite resistance encoded by the Streptococcus pneumoniae tehB gene. FEMS Microbiol. Lett. 174:385-392.
10. Lu TK, Collins JJ. 2009. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U. S. A. 106:4629-4634.
11. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2:489-497.
12. Robillard NJ. 1990. Broad-host-range gyrase A gene probe. Antimicrob. Agents Chemother. 34:1889-1894.
13. Sharan SK, Thomason LC, Kuznetsov SG, Court DL. 2009. Recombineering: a homologous recombination-based method of genetic engineering. Nat. Protoc. 4:206-223.
14. Shen P, Huang HV. 1986. Homologous recombination in Escherichia coli: dependence on substrate length and homology. Genetics 112:441-457.
15. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I. 2007. Detection of streptomycin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by denaturing HPLC analysis and DNA sequencing. Microbes Infect. 9:1538-1544.
16. Sreevatsan S, et al. 1996. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob. Agents Chemother. 40:1024-1026.
17. Sung CK, Li H, Claverys JP, Morrison DA. 2001. An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl. Environ. Microbiol. 67:5190-5196.
18. Timms AR, Steingrimsdottir H, Lehmann AR, Bridges BA. 1992. Mutant sequences in the rpsL gene of Escherichia coli B/r: mechanistic implications for spontaneous and ultraviolet light mutagenesis. Mol. Gen. Genet. 232:89-96.
19. Wiegand I, Hilpert K, Hancock RE. 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3:163-175.
20. Wong QN, et al. 2005. Efficient and seamless DNA recombineering using a thymidylate synthaseAselection system in Escherichia coli. Nucleic Acids Res. 33:e59.
21. Wright A, Hawkins CH, Anggard EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34:349-357.
22. Zannoni D, Borsetti F, Harrison JJ, Turner RJ. 2008. The bacterial response to the chalcogen metalloids Se and Te. Adv. Microb. Physiol. 53:1-72.